PhRMA drums out 22 mem­bers who didn’t make the cut as ma­jor league R&D play­ers

The shake­out at PhRMA is over.

Af­ter be­ing swept up in­to the con­tro­ver­sy that sur­round­ed a cou­ple of its top mem­bers with a no­to­ri­ous­ly itchy trig­ger fin­ger for sky high prices on some unim­pres­sive ther­a­pies, the in­dus­try lob­by­ing group has now com­plet­ed its re­view of their mem­ber­ship rules, com­ing up with some cri­te­ria on who can qual­i­fy for the club.

In a state­ment out to­day, PhRMA notes that mem­bers will have to de­vote at least 10% of their rev­enue to R&D with a min­i­mum re­search bud­get of $200 mil­lion a year — and they have to have main­tained that track record over the last three years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.